Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 7/20 | 0.59 |
| ▸ | MAX | P61244 | 6/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934519 | 0.81 | MYC (0.63) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL17934604 | 0.77 | MYC (0.59) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL25645369 | 0.76 | MYC (0.68) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL17927322 | 0.75 | MAPK1 (0.71) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL17927320 | 0.75 | MAPK1 (0.71) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL20816069 | 0.74 | MYC (1.00) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL20816068 | 0.74 | MYC (1.00) | MYCMAXIGF1RPIM1PIM2 | |
| SCHEMBL20816065 | 0.73 | MYC (1.00) | MYCMAXRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL20816067 | 0.73 | MYC (1.00) | MYCMAXRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL17051283 | 0.71 | MYC (0.76) | MYCMAXNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | UNIVERSITY OF ROCHESTER | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | TEAD2, MYT1, TEAD1 | MYC 32/4885MAX 2012/4885IGF1R 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.